Navigation Links
FDA Approves XYZAL(R) (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies and Chronic Idiopathic Urticaria
Date:2/19/2008

BRUSSELS, Belgium, and BRIDGEWATER, N.J., Feb. 19 /PRNewswire-FirstCall/ -- UCB (Euronext: UCB) and sanofi-aventis announced today that the U.S. Food and Drug Administration (FDA) approved a New Drug Application (NDA) for XYZAL(R) (levocetirizine dihydrochloride) 0.5 mg/mL oral solution, a prescription antihistamine indicated for the relief of symptoms associated with indoor and outdoor allergies, as well as the treatment of chronic idiopathic urticaria. XYZAL(R) tablets received FDA approval on May 25, 2007 and both formulations are now approved for use in adults and children 6 years and older.

"The oral solution of XYZAL(R) provides a welcome alternative for those patients who have difficulty swallowing or who prefer liquid medication," said Michael S. Blaiss, MD, Clinical Professor of Pediatrics and Medicine at the University of Tennessee Health Science Center in Memphis, Tennessee. "Both the oral solution and tablets offer patients powerful and long-lasting allergy relief."

Studies in allergic rhinitis patients demonstrated levocetirizine significantly reduced the symptoms of sneezing, itchy nose, runny nose, and itchy eyes. Studies in chronic idiopathic urticaria patients showed levocetirizine significantly reduced the severity of itching and the number and size of wheals.

In September 2006, UCB and sanofi-aventis entered into an agreement to launch and co-market XYZAL(R) in the U.S. UCB and sanofi-aventis have a long history in the allergy treatment arena and are committed to advancing treatment for allergy sufferers and helping meet unmet medical needs for patients with chronic allergy symptoms.

About Allergic Conditions

Many people suffer from the symptoms associated with common allergic conditions. The immune system of allergy sufferers over-reacts to something in the environment, leading to symptoms that affect their respiratory system, eyes, or skin. Estimates from the American Academy of Allergy, Asthma & Immunol
'/>"/>

SOURCE sanofi-aventis
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
3. FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder
4. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
5. FDA Approves MiddleBrooks Amoxicillin PULSYS for Pharyngitis/Tonsillitis in Adolescents and Adults
6. Tourtellotte Solutions Blazes Trail with New Release of Clinical Trial Supply Chain Simulator
7. Image Solutions, Inc. Acquires Zurich Biostatistics, Inc.
8. Data from Three Clinical Trials for Perforomist(TM) Inhalation Solution to be Presented at CHEST 2007 on October 24, 2007
9. Studies Show Body Mass Index Has No Effect on Resolution and Healing of GERD Symptoms
10. Facet Solutions Enjoys Continued Clinical Success With the Anatomic Facet Replacement System (AFRS(TM))
11. Facet Solutions AFRS(TM) Demonstrates Biomechanical Advantages Over Dynamic Stabilization in Independent Testing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... DUBLIN , Aug. 29, 2014 Research ... CNS Disorders Drug Pipeline Insight 2014" report to their ... market in US is one of the largest segments of ... an alarming rate, while the available therapies were unable to ... growth in the market for CNS disorder, especially over the ...
(Date:8/29/2014)... 29, 2014 According to ... by Extraction type (SFE, Cold Pressed, Organic Solvent, & ... Pharmaceutical, Food Supplements, Fragrance, & Others) - Global Trends ... and segments the Amaranth Seed Oil Market with ... in terms of value. The Amaranth Seed Oil ...
(Date:8/29/2014)... 2014 Does your doctor know what you,re smoking?  ... recommended marijuana to the over 112,000 currently registered patients under ... of the other roughly 20,300+ active physicians listed with the ... it – even though a poll in February 2014 showed ... have tried it. "With marijuana legalization underway, ...
Breaking Medicine Technology:US CNS Disorders Drug Pipeline Insight 2014 2Amaranth Seed Oil Market worth $700.6 Million by 2019 2Amaranth Seed Oil Market worth $700.6 Million by 2019 3Amaranth Seed Oil Market worth $700.6 Million by 2019 4Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 2Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 3Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 4
... 23, 2011 Takeda Pharmaceutical Company Limited (Takeda) ... Center, Inc. U.S., submitted a New Drug Application ... (FDA) for an investigational fixed-dose combination of azilsartan ... hypertension, or high blood pressure. Discovered by Takeda, ...
... (Nasdaq: IDIX ), announced today that Idenix management ... Healthcare Conference on March 2, 2011 at 3:30 p.m. ET ... The live and archived webcast of the ... the Idenix Investor Center at www.idenix.com . Please log ...
Cached Medicine Technology:Takeda Submits New Drug Application in the U.S. for Azilsartan Medoxomil Plus Chlorthalidone, an Investigational Fixed-Dose Combination for the Treatment of Hypertension 2Takeda Submits New Drug Application in the U.S. for Azilsartan Medoxomil Plus Chlorthalidone, an Investigational Fixed-Dose Combination for the Treatment of Hypertension 3
(Date:8/29/2014)... Edvance360, a leading provider of eLearning solutions, ... as well as 2011 winner and six-time-finalist for the ... announced that Brooke Education Services, Northwest Academy, Typewell, Dialysis ... Bureau of Canada (IAB Canada), StarSVCS, and HMG Plus, ... to welcome each new client to the growing Edvance360 ...
(Date:8/29/2014)... 29, 2014 Floors of hospitals and ... wearing socks. Also, many patients are relegated to lying ... surgery recovery, Alzheimer’s, etc. Two inventors from Perrysburg, Ohio, ... patient safety. , This special pair of socks helps ... keeps patients who are relegated to beds or chairs ...
(Date:8/29/2014)... a U.S. Food and Drug Administration (FDA)-approved treatment ... is as effective at reducing fracture risk as ... suppressing bone loss. With the use of wide- ... researchers carried out experiments at the U.S. Department ... Argonne National Laboratory that revealed an additional mechanism ...
(Date:8/29/2014)... the Washington University School of Medicine have identified one ... providing important insight that could lead to new therapies, ... Cell Host & Microbe . , In work ... Photon Source, the researchers developed a detailed map of ... host protein that takes signaling molecules in and out ...
(Date:8/29/2014)... August 30, 2014 Top10inaction, a professional ... conference providers in the online service industry for the ... global leaders Webex, GotoMeeting and Infinite. , With over ... have to determine which provider is ideally a good ... businesses search for compelling consumer goods and services agencies ...
Breaking Medicine News(10 mins):Health News:Edvance360 Continues to Experience Growth in Corporate, K-12, Health, and Non-Profit Sectors 2Health News:Revealing a novel mode of action for an osteoporosis drug 2Health News:Top10InAction Reveals Best Web Conference Providers 2
... Blue Plan Experienced a 15 Percent Increase ... a New Report from HealthLeaders-InterStudy, NASHVILLE, ... of managed care market intelligence, reports that ... medication use,through pharmacy programs and public education ...
... Health,Care Systems, Inc. (HCS), a leading provider ... medication reconciliation solutions, has entered,into an agreement with ... not-for-profit hospitals in the nation with 881 licensed,acute ... facility for The,University of Alabama at Birmingham,s Family ...
... treatment could help 3.3 million U.S. sufferers, ... Medical, Inc. today,announced that 98.4 percent of ... called Barrett,s esophagus were free of the ... the HALO ablation,system. The results were published ...
... release of milk in humans, animals , , FRIDAY, July 18 ... speaking? , Researchers have discovered that babies nursing at ... to release of oxytocin, known as the "trust" hormone in ... to be involved in trust and love in both humans ...
... restored brain,s ability to make new cells , , FRIDAY, July ... day may lead to health issues, including depression, a new ... a causal link between abstinence from alcohol drinking and depression," ... and pharmacology in the University of North Carolina School of ...
... in French . , Winnipeg (July ... Canadian Institutes of Health Research (CIHR) was announced today ... Secretary for Health, on behalf of Tony Clement, Minister ... investigating how to improve the application of mental health ...
Cached Medicine News:Health News:New York's Excellus BlueCross BlueShield to Continue Generic Medication Promotion to Help Control Costs 2Health News:Huntsville Hospital Signs With Health Care Systems, Inc. for Automated Medication Reconciliation Services 2Health News:Precancerous Esophagus Disease Eliminated in 98.4% of Patients Treated With HALO Ablation System 2Health News:Precancerous Esophagus Disease Eliminated in 98.4% of Patients Treated With HALO Ablation System 3Health News:Suckling Infant Triggers 'Trust' Hormone in Moms 2Health News:Research Finds Causal Link Between Ending Drinking, Depression 2Health News:CIHR announces $4.4 million to improve mental health of Canadians 2
P-Series Cystourethroscope Short Bridge, examining...
Short double-horn bridge for insertion of instruments...
Designed for accurate articulation of flexible devices....
... Used for stone manipulation and removal in the ... basket to retain its shape following extreme torsion. ... capture by allowing the basket to open at ... stone. The tipless design reduces the likelihood of ...
Medicine Products: